Report Code: A13321 | Nov 2023 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Fetal Valproate Syndrome Market
Request Now !Fetal valproate syndrome may be developed in the babies if the mother or the baby is exposed to valproic acid during the early stages of pregnancy. Valproic acid is used in the treatment of epilepsy, bipolar disorder, and migraines. Pregnant women who consume valproic acid are at risk of developing fetal valproate syndrome, wherein the baby may have one or more birth defects such as genital abnormalities. This syndrome develops when the mother takes more than 800 mg/day of valproic acid from the first to the third month of pregnancy.
COVID-19 Impact Analysis            Â
COVID-19 is an infectious disease that first emerged in late December in Hubei province of the Wuhan city in China in late December. The virus that causes, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly infectious and is transmitted from person to person. Since the outbreak in December 2019, the disease has spread to almost 213 countries across the globe with the World Health Organization declaring it a pandemic on March 11, 2020.
Pharmaceutical and biotech companies along with the governments around the globe are working to address the COVID-19 outbreak, from supporting the vaccines development to medicine supply chain planning. Approximately, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a significant increase in demand for the treatment of COVID-19. Such increased demand for these drugs has presented huge opportunities for manufacturers of COVID-19 treatment drugs, as many developed countries are experiencing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future due to the demand for vaccine and the treatment drugs for COVID-19. This is expected to have a significant impact on the fetal valproate syndrome market.
Top Impacting Factors
Market Trend
New Product Launches to Flourish the Market
Alkermes announced FDA approval to launch LYBALVI with Olanzapine and Samidorphan in 2021. LYBALVI is can be used to treat bipolar disorder.
GSK consumer Healthcare partnered with Smile Train to launch Smile Change Lives in 2021. This will help in the treatment and surgery of infants born with cleft lip & palate caused due to any disorders such as fetal valproate syndrome.
Key Benefits of the Report
Questions Answered in the Fetal Valproate Syndrome Market Report    Â
Fetal Valproate Syndrome Market Report Highlights
Aspects | Details |
---|---|
By Symptom |
|
By Gender |
|
By Treatment |
|
By Region |
|
Key Market Players | Wellona Pharma, Aspire Pharma Limited, Healthy Life Pharma Private Limited, Sanofi, Taj Pharmaceuticals Limited, Desitin Pharma Ltd, REWINE PHARMACEUTICAL, Sun Pharmaceutical Industries Ltd, SALVAVIDAS PHARMACEUTICAL PVT. LTD., Anjan Drug Pvt. Ltd. |
Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers